Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
TOT BIOPHARM International Co. Ltd. ( (HK:1875) ) just unveiled an announcement.
BioDlink International Company Limited has officially changed its English name from TOT BIOPHARM International Company Limited, effective July 11, 2025, following shareholder approval. This change is accompanied by amendments to the Articles of Association, a new stock short name ‘BIODLINK-B’ effective July 30, 2025, a new website address, and a new company logo, reflecting the company’s rebranding efforts.
The most recent analyst rating on (HK:1875) stock is a Buy with a HK$3.00 price target. To see the full list of analyst forecasts on TOT BIOPHARM International Co. Ltd. stock, see the HK:1875 Stock Forecast page.
More about TOT BIOPHARM International Co. Ltd.
BioDlink International Company Limited, formerly known as TOT BIOPHARM International Company Limited, operates in the biopharmaceutical industry. The company focuses on developing and manufacturing oncology drugs and therapies, aiming to address unmet medical needs in the cancer treatment market.
Average Trading Volume: 159,915
Technical Sentiment Signal: Buy
Current Market Cap: HK$1.92B
For detailed information about 1875 stock, go to TipRanks’ Stock Analysis page.